#Nuclear Medicine or Radiopharmaceuticals Market Nuclear Medicine or Radiopharmaceuticals Market Size Nuclear Medicine or Radiopharmaceutical | Explore Tumblr Posts and Blogs

credenceresearchdotblog · 2 months

Text

The global demand for medical imaging reagents was valued at USD 16251.2 Million in 2023 and is expected to reach USD 25646.4 Million in 2032, growing at a CAGR of 5.2% between 2024 and 2032.Medical imaging reagents are essential in modern healthcare, significantly enhancing the diagnostic accuracy and treatment efficacy of various diseases. These reagents, including contrast media, radiopharmaceuticals, and fluorescent dyes, are used to visualize structures and functions within the body, aiding in the early detection, diagnosis, and monitoring of diseases. The global medical imaging reagents market has seen substantial growth, driven by technological advancements, an aging population, and increasing prevalence of chronic diseases.

Browse the full report at https://www.credenceresearch.com/report/medical-imaging-reagents-market

Market Overview

The medical imaging reagents market encompasses a variety of products that improve the visibility of internal organs, tissues, and systems in imaging procedures. These reagents are used in various imaging modalities, including:

1. X-ray and Computed Tomography (CT) 2. Magnetic Resonance Imaging (MRI) 3. Nuclear Medicine Imaging (PET and SPECT) 4. Ultrasound 5. Optical Imaging

Each modality requires specific types of reagents to enhance image clarity and detail. The primary categories of imaging reagents are:

- Contrast Media: Used to enhance the contrast of structures or fluids within the body, making them more visible on imaging. - Radiopharmaceuticals: Radioactive compounds used in nuclear medicine to diagnose and treat diseases. - Fluorescent Dyes: Used in optical imaging to highlight specific areas of interest.

Key Drivers

1. Technological Advancements: Continuous innovations in imaging technologies and the development of new and improved reagents have significantly contributed to market growth. For example, advancements in MRI contrast agents have led to better image quality and reduced side effects. 2. Aging Population: The global increase in the elderly population has led to a higher incidence of chronic diseases such as cancer, cardiovascular diseases, and neurological disorders. This demographic shift has increased the demand for diagnostic imaging procedures.

3. Prevalence of Chronic Diseases: The rising prevalence of chronic diseases, including cancer, diabetes, and cardiovascular diseases, has driven the need for advanced diagnostic tools. Early diagnosis through imaging is crucial for effective treatment and management of these conditions.

4. Growing Awareness and Screening Programs: Increased awareness about the benefits of early diagnosis and the implementation of screening programs for various diseases have boosted the demand for imaging procedures, thereby driving the market for imaging reagents.

Market Segmentation

The medical imaging reagents market can be segmented based on product type, application, and geography.

1. Product Type: - Contrast Media - Radiopharmaceuticals - Fluorescent Dyes

2. Application: - Oncology - Cardiology - Neurology - Gastroenterology - Others

3. Geography: - North America - Europe - Asia-Pacific - Latin America - Middle East & Africa

Regional Insights

North America: Dominates the medical imaging reagents market, driven by advanced healthcare infrastructure, high healthcare expenditure, and a strong focus on research and development.

Europe: Follows closely, with significant investments in healthcare and increasing adoption of advanced imaging technologies.

Asia-Pacific: Expected to witness the fastest growth due to the rising healthcare expenditure, growing awareness about early diagnosis, and an increasing number of diagnostic imaging procedures.

Latin America and Middle East & Africa: These regions are also expected to see growth due to improving healthcare infrastructure and increasing adoption of advanced medical technologies.

Challenges and Opportunities

Challenges: - High Cost: The high cost of imaging procedures and reagents can be a barrier, especially in developing regions. - Side Effects: Some imaging reagents, particularly contrast media, can cause adverse reactions in patients, which can limit their use.

Opportunities: - Personalized Medicine: The growing trend of personalized medicine offers significant opportunities for the development of targeted imaging reagents. - Emerging Markets: Developing regions present substantial growth opportunities due to the expanding healthcare sector and increasing demand for advanced diagnostic tools.

Key Players

Bracco Spa

Lantheus Holdings Inc

General Electric Company

Siemens AG

Bayer AG

CMC Contrast AB

Thermo Fisher Scientific Inc

Merck & Co. Inc

Shimadzu Corporation

Koninklijke Philips N.V.

Others

Segmentation

By Type of Reagents

Contrast Agents

Iodinated Contrast Agents

Gadolinium-Based Contrast Agents

Barium-Based Contrast Agents

Microbubble Contrast Agents (used in ultrasound)

Nuclear Imaging Reagents

Technetium

Fluorine

Gallium

Thallium

Fluorescent Dyes

Bioluminescent Substrates

Others

By Imaging Modality

Computed Tomography (CT)

Magnetic Resonance Imaging (MRI)

Positron Emission Tomography (PET)

Ultrasound

X-ray

Nuclear Medicine

By Application

Cardiology

Oncology

Neurology

Orthopedics

Gastroenterology

Nephrology

Others

By End-User

Hospitals and Clinics

Diagnostic Imaging Centers

Research Institutes

Pharmaceutical and Biotechnology Companies

By Product Formulation

Ready-to-use Reagents

Dry Powder Reagents

Liquid Reagents

By Isotope

Radioactive Isotopes

Non-radioactive Isotopes

By Region

North America

The U.S.

Canada

Mexico

Europe

Germany

France

The U.K.

Italy

Spain

Rest of Europe

Asia Pacific

China

Japan

India

South Korea

South-east Asia

Rest of Asia Pacific

Latin America

Brazil

Argentina

Rest of Latin America

Middle East & Africa

GCC Countries

South Africa

Rest of the Middle East and Africa

Browse the full report at https://www.credenceresearch.com/report/medical-imaging-reagents-market

About Us:

Credence Research is committed to employee well-being and productivity. Following the COVID-19 pandemic, we have implemented a permanent work-from-home policy for all employees.

Contact:

Credence Research

Please contact us at +91 6232 49 3207

Email: [email protected]

Website: www.credenceresearch.com

0 notes

health-views-updates · 5 months

Text

Growth Factors of Medical Isotope Market with Emerging Trends and Revenue Estimation By 2031

The latest market analysis report on the Canada Medical Isotope market unveils a promising trajectory, indicating substantial growth potential over the forecast period from 2024 to 2031. According to the report, the market size for Canada was valued at USD 911.17 million in 2022 and is anticipated to soar to USD 2.22 billion by 2031, representing a remarkable CAGR of 11.8%.

Market Analysis:

The Canada Medical Isotope market is witnessing significant growth owing to the increasing prevalence of chronic diseases, rising adoption of nuclear medicine in diagnostic and therapeutic applications, and advancements in radiopharmaceuticals. Isotopes play a crucial role in medical imaging and therapy, driving demand in oncology, cardiology, neurology, and other medical specialties.

Read Full Report @ https://www.snsinsider.com/reports/medical-isotope-market-2670

Emerging Trends and Opportunities:

Emerging trends in the Canada Medical Isotope market include the development of novel production techniques, such as cyclotron-based production, to mitigate supply chain vulnerabilities. Additionally, the integration of artificial intelligence and machine learning in nuclear medicine is poised to revolutionize diagnostics and treatment planning, presenting lucrative opportunities for market players.

Get Free Sample Report @ https://www.snsinsider.com/sample-request/2670

Key Drivers Propelling Growth:

The market growth is primarily propelled by the escalating demand for nuclear imaging procedures, the rising incidence of cancer and cardiovascular diseases, and the expanding applications of medical isotopes in personalized medicine. Moreover, government initiatives to enhance healthcare infrastructure and promote nuclear medicine technologies are bolstering market expansion.

Challenges and Considerations:

Despite the promising growth prospects, the Canada Medical Isotope market faces challenges related to regulatory complexities, high capital requirements for infrastructure development, and concerns regarding radiation safety. Additionally, geopolitical tensions and supply chain disruptions pose risks to isotope production and distribution.

Key Takeaways from the Market:

Growing demand for diagnostic imaging procedures fuels market expansion.

Technological advancements drive innovation and diversification in radiopharmaceuticals.

Strategic collaborations and partnerships are vital for enhancing production capacity and ensuring supply chain resilience.

Regulatory compliance and adherence to safety standards are imperative for sustainable market growth.

The Canada Medical Isotope market is poised for robust growth in the coming years, driven by evolving healthcare needs, technological innovations, and strategic investments. Market participants are urged to capitalize on emerging opportunities and address challenges proactively to maintain a competitive edge in this dynamic landscape.

0 notes

blueweave · 8 months

Text

Middle East and Africa Radiopharmaceuticals Market size at USD 0.21 billion in 2023. During the forecast period between 2024 and 2030, BlueWeave expects the Middle East and Africa Radiopharmaceuticals Market size to grow at a CAGR of 6.01% reaching a value of USD 0.29billion by 2030. The Middle East and Africa Radiopharmaceuticals Market is driven by the increasing prevalence of chronic diseases, rising adoption of nuclear medicine for diagnosis and treatment, and growing awareness about advanced medical imaging techniques. Additionally, expanding healthcare infrastructure, rising investments in research and development, and supportive government initiatives contribute to market growth. The demand for radiopharmaceuticals is further fueled by the aging population, technological advancements in nuclear medicine, and the rising incidence of cancer. These factors collectively enhance the diagnostic and therapeutic capabilities of radiopharmaceuticals, fostering market expansion in the Middle East and Africa.

Opportunity – Innovative nuclear medicine breakthroughs

The advancements of nuclear medicine technologies in the Middle East and Africa region are driving the Radiopharmaceuticals Market in the region. Pioneering breakthroughs, such as cutting-edge imaging and therapeutic applications, are revolutionizing healthcare practices. The synergy of evolving diagnostic capabilities and targeted treatments is reshaping the medical landscape, propelling the market forward, and ensuring a brighter, more precise future for patient care in the region.

Impact of Escalating Geopolitical Tensions on Middle East and Africa Radiopharmaceuticals Market

Escalating geopolitical tensions in the Middle East and Africa pose significant challenges to the growth of Radiopharmaceuticals Market in the region. Uncertainties in the region disrupt supply chains, hindering the production and distribution of essential radiopharmaceuticals. Increased political instability may also deter foreign investments and collaborations, limiting technological advancements and research initiatives. In such an environment, regulatory frameworks may face delays, impacting market approvals and market entry for innovative products. Additionally, heightened geopolitical risks may lead to fluctuating currency values, affecting pricing strategies and overall market dynamics. The Middle East and Africa Radiopharmaceuticals Market could experience reduced growth and innovations, as geopolitical tensions create an unpredictable and challenging business environment for stakeholders in the industry.

Sample Request @ https://www.blueweaveconsulting.com/report/middle-east-and-africa-radiopharmaceuticals-market/report-sample

#Blueweave #Consulting #marketresearch #marketforecast #healthcare

0 notes

healthcareruhi · 9 months

Text

Global Nuclear Medicine Market Size, Trends, Analysis, Growth, Share, Industry Forecast, 2023-2030

Global Nuclear Medicine Market

The Global Nuclear Medicine Market was valued at US$ 5.97 Bn in 2022 estimated to reach US$ 11.59 Bn by 2030, with a CAGR of 8.33% from 2023-2030. In the field of medicine known as nuclear medicine, numerous ailments such as cancer, cardiac disease, and neurological problems are diagnosed and treated using radioactive materials called radiopharmaceuticals. High-tech cameras allow medical personnel to monitor the radioactive tracers' progress. Additionally, two essential imaging modalities in nuclear medicine are single-photon emission computed tomography (SPECT) and positron emission tomography (PET).

Read More: https://qualiketresearch.com/reports-details/Global-Nuclear-Medicine-Market

Market Drivers

The availability of a strong product pipeline and supportive government programs to increase accessibility to nuclear medicine is anticipated to drive market growth in the coming years. Clinical trials are being conducted on several products, such as betalains, omburtamab, yttrium-90 microspheres, PNT2003, and 177Lu-PNT2002. The U.S. has a favorable reimbursement environment for radiopharmaceuticals is expected to stimulate market expansion. In addition, therapy requirements for patients are growing improvements in disease diagnosis and therapy as well as the approval of novel nuclear medicine-based technologies. For instance, GE Healthcare announced in September 2021 the introduction of a unique scanner with a new automated workflow feature that delivers an excellent view of cardiac anatomy and pathology to aid physicians in selecting the best course of treatment for a patient.

Market Segmentation

The scope of the Global Nuclear Medicine Market covers segmentation based on Diagnostics, Therapeutics, Applications, and Region. Based on Diagnostics, the market is segmented into Single Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET). Based on Therapeutics, the market is classified into Alpha Emitters, Beta Emitters, and Brachytherapy. Based on Applications, the market is bifurcated into Cardiology, Neurology, Oncology, and Other Applications.

Request A Sample: https://qualiketresearch.com/request-sample/Global-Nuclear-Medicine-Market/request-sample

Regional Analysis

The Global Nuclear Medicine Market is segmented into 5 main regions, namely, North America, Europe, Asia Pacific, Middle East and Africa, and Latin America. The primary market for nuclear medicine is North America.

The United States' booming healthcare industry, rising cancer rates, rising geriatric population, rise in product launches driving up radioisotope usage, and increased initiatives and investments in cutting-edge healthcare solutions for cancer treatment are all expected to contribute to the market's expansion. In the United States, funding for cancer illness research and treatment is likewise rising. The National Centre for Health Statistics (NCHS) of the Centres for Disease Control & Prevention (CDC) has produced data that estimates cancer-related investments might reach up to USD 7,176 million in 2021.

Key Developments The Department of Nuclear Medicine at PSG Hospitals in Coimbatore, which is outfitted with cutting-edge technology for diagnosing cancer and other disorders, was opened in April 2022 by Health Minister Ma. Subramanian. A program enabling nuclear medicine facilities the chance to become designated and certified Centres of Excellence in Radiopharmaceutical Therapy was introduced by SNMMI in February 2022. Strict regulatory, training, certification, experience, and performance standards will be met by the centers, resulting in optimal patient selection and radiopharmaceutical therapy outcomes. Key Players

Mallinckrodt plc., General Electric Co., Medtronic, plc. (Covidien, acquired by Medtronic), Bayer AG, Cardinal Health, Inc., Lantheus Medical Imaging, Inc., IBA Group, Bracco Imaging S.p.A, NTP Radioisotopes SOC Ltd., Advanced Accelerator Applications S.A.

Key Questions Addressed by the Report • What are the Key Opportunities in Global Bonsai Market? • What will be the growth rate from 2023 to 2030? • Which segment/region will have the highest growth? • What are the factors that will impact/drive the Market? • What is the competitive Landscape in the Industry? • What is the role of key players in the value chain?

About Us:

QualiKet Research is a leading Market Research and Competitive Intelligence partner helping leaders across the world to develop robust strategy and stay ahead for evolution by providing actionable insights about ever changing market scenario, competition and customers.

QualiKet Research is dedicated to enhancing the ability of faster decision making by providing timely and scalable intelligence.

QualiKet Research strive hard to simplify strategic decisions enabling you to make right choice. We use different intelligence tools to come up with evidence that showcases the threats and opportunities which helps our clients outperform their competition. Our experts provide deep insights which is not available publicly that enables you to take bold steps.

6060 N Central Expy #500 TX 75204, U.S.A

[email protected]

+1 214 660 5449

1201, City Avenue, Shankar Kalat Nagar,

Wakad, Pune 411057, Maharashtra, India

[email protected]

+91 9284752585

Sharjah Media City , Al Messaned, Sharjah, UAE.

[email protected]

+91 9284752585

#Nuclear Medicine Market

0 notes

ellinapark · 1 year

Text

Radiopharmaceuticals in Nuclear Medicine Market to Eyewitness Massive Growth by 2028

The Latest Released market study on Global Radiopharmaceuticals in Nuclear Medicine market provides information and useful stats on market structure, size and trends. The report is intended to provide cutting-edge market intelligence and strategic insights to help decision makers take sound investment decisions and identify potential gaps and growth opportunities. Besides, the report also identifies and analyses changing dynamics, emerging trends along with essential drivers, challenges, opportunities and restraints in Radiopharmaceuticals in Nuclear Medicine market. What’s keeping:

Cardinal Health (United States)

GE Healthcare (United States)

Curium (France)

Lantheus Medical Imaging (United States)

Bayer AG (Germany)

Bracco Imaging (Italy)

EczacÃ½baÃ¾Ã½-Monrol Nuclear Products (Turkey)

Nordion (Canada)

Advanced Accelerator Applications (France)

NTP Radioisotopes (South Africa)

Keep Growing in the Market? Benchmark yourself with the strategic moves and latest Market Share and Sizing of Global Radiopharmaceuticals in Nuclear Medicine market recently published by AMA Radiopharmaceuticals are radioactive compounds that have a bound radionuclide in their structure, whose purpose is directing the radionuclide to a location to be treated or to obtain images. Nuclear medications, also known as radiopharmaceuticals, are used to treat lymphoma and bone metastases. Nuclear medicines such as F-18, Tc-99, Ga-67, and I-123 are used in diagnostic operations, while I-131, Ir-192, Y-90, I-125, Lu-177, and Ra-223 are employed in therapeutic procedures. In comparison to chemotherapy, the convenience of treatment using minimally invasive approaches attracts more people to radiopharmaceuticals. The radiopharmaceuticals industry is driven by the rising number of cardiac patients and the development of clear imaging techniques using diagnostic equipment such as PET and SPECT. Supply constraints, logistical challenges, and a scarcity of skilled medical professionals are among the problems limiting the market's growth.

The Radiopharmaceuticals in Nuclear Medicine Market segments and Market Data Break Down 24360

On the geographical front, the market has been segregated into North America (the United States and Canada), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia and others), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia and others), Latin America (Brazil, Mexico and others), and Middle East and Africa. What’s Trending in Market: High Demand due to increasing Initiatives to reduce the demand and supply gap of Mo-99

Market Challenges: Hospital budget cuts and high equipment costs

Market Opportunities: Use of radiopharmaceuticals in neurological applications

Highlights of Influencing Drivers: Rising incidence as well as prevalence of target conditions

Huge Development of alpha-radioimmunotherapy-based targeted cancer treatments

Presented By

AMA Research & Media LLP

0 notes

latestsmarkettrends · 1 year

Text

0 notes

delvenservices · 1 year

Text

Nuclear Medicine/Radiopharmaceuticals Market – Trends Forecast Till 2028

Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90)), Application (Oncology, Cardiology), Procedures and Region (North America, Europe, Asia-Pacific, Middle East and Africa and South America)

The Nuclear Medicine/Radiopharmaceuticals Market size is projected to reach a CAGR of 10.1% from 2021 to 2028.

Radiopharmaceuticals are pharmaceutical formulations comprising radioactive isotopes that are used in diagnosis and therapeutics. They are simple and small substances that contain a radioactive substance that is used in the treatment of cancer and cardiac & neurological disorders.

Increasing incidence and prevalence of cancer and cardiac ailments and initiatives to lessen the demand-supply gap of Mo-99 are some of the factors that have supported long-term expansion for Nuclear Medicine/Radiopharmaceuticals Market.

Request For Free Sample Report: https://www.delvens.com/get-free-sample/radiopharmaceuticals-market-trends-forecast-till-2028

Regional Analysis

North America is expected to account for the largest share of the nuclear medicine market during the forecast period, The large share of North America can be attributed to the development of novel technologies for radioisotope production, government funding, increasing R&D expenditure and company initiatives in the region.

Key Players

Mallinckrodt plc.

General Electric Co. (healthcare division)

Medtronic, Inc.

Bayer AG

Cardinal Health, Inc.

Lantheus Medical Imaging, Inc.

IBA Group

Make an Inquiry Before the Purchase: https://www.delvens.com/Inquire-before-buying/radiopharmaceuticals-market-trends-forecast-till-2028

Recent Developments

In 2021, Bracco entered into a partnership with CardioNavix which will help improve patient access to cardiac PET imaging.

In 2019. Curium acquired MAP Medical, which will help it to increase its footprint in Europe with direct access to Nordic and Baltic countries.

Reasons to Acquire

Increase your understanding of the market for identifying the best and suitable strategies and decisions on the basis of sales or revenue fluctuations in terms of volume and value, distribution chain analysis, market trends and factors

Gain authentic and granular data access for Nuclear Medicine/Radiopharmaceuticals Market so as to understand the trends and the factors involved behind changing market situations

Qualitative and quantitative data utilization to discover arrays of future growth from the market trends of leaders to market visionaries and then recognize the significant areas to compete in the future

In-depth analysis of the changing trends of the market by visualizing the historic and forecast year growth patterns

Purchase This Report At: https://www.delvens.com/checkout/radiopharmaceuticals-market-trends-forecast-till-2028

Report Scope

Nuclear Medicine/Radiopharmaceuticals Market is segmented into type, application, procedural volume assessment and region.

On the basis of Type

Diagnostic Nuclear Medicine

Therapeutic Nuclear Medicine

Brachytherapy Isotopes

On the basis of Application

Diagnostic Applications

On the basis of Procedural Volume Assessment

Diagnostic Procedures

Therapeutic Procedures

On the basis of Region

Asia Pacific

North America

Europe

South America

Middle East & Africa

About Us:

Delvens is a strategic advisory and consulting company headquartered in New Delhi, India. The company holds expertise in providing syndicated research reports, customized research reports and consulting services. Delvens qualitative and quantitative data is highly utilized by each level from niche to major markets, serving more than 1K prominent companies by assuring to provide the information on country, regional and global business environment. We have a database for more than 45 industries in more than 115+ major countries globally.

Delvens database assists the clients by providing in-depth information in crucial business decisions. Delvens offers significant facts and figures across various industries namely Healthcare, IT & Telecom, Chemicals & Materials, Semiconductor & Electronics, Energy, Pharmaceutical, Consumer Goods & Services, Food & Beverages. Our company provides an exhaustive and comprehensive understanding of the business environment.

UNIT NO. 2126, TOWER B,

21ST FLOOR ALPHATHUM

SECTOR 90 NOIDA 201305, IN

+44-20-8638-5055

[email protected]

0 notes

waquasuniverse · 1 year

Text

Nuclear Medicine Market Size To Reach $22.3Bn By 2030

The global nuclear medicine market size is expected to reach USD 22.3 billion by 2030, registering a CAGR of 11.8% over the forecast period, according to a new report by Grand View Research, Inc. The increasing prevalence of chronic diseases such as cancer & thyroid is anticipated to drive market growth. The impending approval of multiple radiopharmaceutical therapeutics during the forecast…

View On WordPress

0 notes

impossibledeanmakerwombat · 1 year

Text

Radiopharmaceuticals Market Size, Share, Trends, Industry Analysis : Research Methodology By Forecast to 2032

As per Future Market Insights (FMI), driven by rising cases of cancer and cardiovascular diseases, radiopharmaceutical market registered steady year-on-year growth Future Market Insights (FMI) predicted that the market for radiopharmaceuticals would be valued US$ 6.2 billion in 2022. The market for radiopharmaceuticals is expected to grow at a value CAGR of 4.3% between 2022 and 2032, reaching US$ 9.5 billion.

Increasing preference of non-invasive medical therapies and production of radioisotopes for the treatment is another factor that will stabilize the growth of radiopharmaceuticals market. Based on this, FMI projects the market is poised to expand at over 4.66% CAGR during the forecast period of 2021 and 2031.

Government initiatives and research activities undertaken to develop advanced radioisotopes for the treatment of cancer and to develop novel therapeutics will boost the demand. Also, introduction of novel technologies such as Positron Emission Technology and others in nuclear imaging systems will bolster growth.

Although, with increasing development activities and increasing commercialization of radiopharmaceuticals by industry giants have picked up the pace for the growth of market. Alongside this, increasing cases of cancer will accelerate the development of nuclear medicines in the field of radiopharmaceuticals.

Request Sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-1992

Prominent Players:

Siemens AG

Positron Corporation

Novartis (Advanced Accelerator Applications)

Curium

GE Healthcare

Lantheus Holdings Inc.

Sotera Health LLC

Bayer AG

Eckert & Ziegler

Key Takeaways from FMI’s Radiopharmaceuticals Market Study

In terms of application, oncology will contribute over 50% of global market share owing to the rising prevalence of cancer across the globe. Cyclotrons are expected to be the primary source of radiopharmaceuticals, accounting for maximum market share Based on radioisotope type, technetium-99 will remain highly preferred radioisotope in the global radiopharmaceutical market The U.S. will retain its global dominance backed by the high cancer and cardiovascular cases rising in the country India will emerge as lucrative market owing to the favorable government initiatives promoting the radiopharmaceuticals market Germany and the U.K. are spearheading the growth of Europe market, which is projected to grow at over 4.9% CAGR

“Increasing research and development initiatives aimed at the production of advanced radioisotopes and novel technologies will improve growth prospects for the leading players in the radiopharmaceuticals market,” says the FMI analyst.

Get a Customized Scope to Match Your Need Ask an Expert@ https://www.futuremarketinsights.com/ask-question/rep-gb-1992

Competitive Landscape

Leading radiopharmaceuticals market players are focusing on expanding their customer base through strategic mergers and acquisition. Increasing research and development activities to develop advanced radioisotopes for the cancer treatment is another core strategy adopted by leading players.

Top 5 players including Siemens AG, GE Healthcare, Curium, Lantheus Holdings Inc., and Eckert & Ziegler are dominating the global radiopharmaceuticals market, contributing over 90% of revenue share.

In March 2021, Novartis announced the commercialization and obtained the rights to develop the therapeutic applications of Fibroblast Activation Protein (FAP) targeting agents including FAPI-46 and FAPI-74, through an assignment agreement with iTheranostics, Inc., an affiliate of SOFIE Biosciences, Inc.

Along with it the company announced the production and commercialization of new nuclear medicine, 18F sodium fluoride radiopharmaceutical in France.

In November 2020, Blue Earth Diagnostics, a leading molecular imaging diagnostic company, unveiled that their manufacturing company, Nucleis has manufactured and shipped their first doses of rhPSMA-7.3 (18F), an investigational Prostate-Specific Membrane Antigen (PSMA)-targeted radiohybrid PET imaging agent, for patients with prostate cancer.

Another industry giant, Jubilant Pharma Limited Company, in 2019, announced the integration of its radiopharmaceutical drug development and manufacturing business with its radio-pharmacy business into a global radiopharmaceutical brand, Jubilant Radiopharma.

For in-depth competitive analysis Buy Now @ https://www.futuremarketinsights.com/checkout/1992

Radiopharmaceuticals Market by Category

By Radioisotope Type:

Technetium-99

Fluorine-18

Iodine-131

Leutetium-177

Yttrium-90

Gallium-68

Gallium-67

Rubidium-82

Iodine-123

Iodine-125

Indium-111

Others

By Application:

Oncology

Cardiology

Gastroenterology

Neuroendocrinology

Neurology

Nephrology

Others

By Source:

Cyclotrons

Nuclear Reactors

By End-User:

Hospitals

Diagnostic Imaging Centers

Ambulatory Surgical Centers

Cancer Research Institute

By Region:

North America

Latin America

Western Europe

Eastern Europe

Asia Pacific excluding Japan

Japan

Middle East & Africa (MEA)

0 notes

vicky8588 · 1 year

Text

Radiopharmaceuticals Market

The “Radiopharmaceuticals Market” size was valued at USD 6,242.80 million in 2021 and is estimated to reach a compound annual growth rate CAGR of 6.2% over the forecast period 2023 to 2030. Radiopharmaceuticals are a class of pharmaceutical medicines with a significant radioactivity level. Radiopharmaceuticals are pharmaceuticals formulations that contain radioactive isotopes. These medications can be administered intravenously, orally, or interstitially. In addition, compared to X-rays and other external radiation imaging systems, it is a suitable and secure alternative for patients and aids physicians in diagnosis.

Radiopharmaceuticals and nuclear medicine are increasingly utilized in diagnostic imaging and radiotherapy. This has paved the way for the market expansion of radiopharmaceuticals. Nuclear medicine and radiopharmaceuticals aid in diagnosing organs affected by any pathological condition, particularly malignancy. This modality's applications have expanded from oncology to cardiology, neurology, and infection detection due to the rapid development of nuclear imaging technologies, particularly PET/PET-CT.

To Get a Free Sample Click here

Radiopharmaceuticals Market Dynamics:

Drivers:

The radiopharmaceuticals market is driven by several factors, including:

Increasing prevalence of cancer: With the rising incidence of cancer, the demand for radiopharmaceuticals is increasing as they are used in cancer diagnosis, staging, and treatment.

Growing demand for nuclear medicine: Radiopharmaceuticals are an essential part of nuclear medicine, which is increasingly being used for the diagnosis and treatment of various diseases.

Technological advancements in imaging modalities: The development of new imaging modalities, such as PET/CT and SPECT/CT, is driving the demand for radiopharmaceuticals, as these modalities require the use of radiopharmaceuticals.

Favorable regulatory policies: Governments are implementing favorable policies and regulations to promote the use of radiopharmaceuticals in healthcare, which is driving the growth of the market.

Increasing investment in research and development: Pharmaceutical companies are investing heavily in research and development to develop new radiopharmaceuticals and improve the existing ones, which is driving the growth of the market.

Rising geriatric population: With the increasing geriatric population, the incidence of chronic diseases is on the rise, which is driving the demand for radiopharmaceuticals in diagnosis and treatment.

Growing awareness about the benefits of nuclear medicine: As the awareness about the benefits of nuclear medicine and radiopharmaceuticals is increasing among patients and healthcare professionals, the demand for these products is also increasing.

Restraints:

Side-Effects of Radiopharmaceuticals

Numerous adverse effects of radiopharmaceuticals inhibit market expansion. Among the side effects are chills, severe lethargy, difficulty breathing, flushing or redness of the skin, nausea or vomiting, skin rash, hives, itching, severe headache, and abdominal pain. Therefore, these factors inhibit market expansion.

This radiopharmaceuticals market report provides details of new developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographies served, and competitive landscape. For more information on the radiopharmaceuticals market, contact Data Bridge Market Research for an Analyst Brief; our team will assist you in making well-informed decisions for market expansion.

Opportunities:

Increasing Demand for Nuclear Imaging Technologies

The development of nuclear imaging technologies, such as PET or PET-CT, has aided in expanding the applications of this modality from oncology to cardiology, neurology, and infection detection. These technological advances have significantly increased the number of PET and SPECT procedures. In the United States, approximately 2,220,300 PET treatments were performed in 2020, up from 2,200,800 in 2019. Consequently, it is anticipated that this factor will increase radiopharmaceutical market revenue.

Growing R&D Activities Associated with Radiopharmaceuticals

Increased radiopharmaceutical-related R&D activities enhanced market growth. In 2022, for example, the first patient dosed in phase III clinical trials for PET radiopharmaceutical imaging agents developed by GE Healthcare was initiated. The strategic approach will help to enhance patient care by identifying adult Parkinson's disease with greater precision. GE Healthcare will expand its radiation patent portfolio. Thus, this factor stimulates market expansion.

Market Segmentation Analysis:

The global Radiopharmaceuticals Market” is Segmented by Radioisotopes, Application, Source, End-user, and Region.

By Radioisotopes

Tec.99

F18

Iodine 131

Lutetium 177

Yttrium 90

Gallium 68

Gallium 67

Rubidium 82

Iodine 123

Iodine 125

Indium 111

Others

By Application

Oncology

Cardiology

Gastroenterology

Neuroendocrinology

Neurology

Nephrology

Others

By Source

Cyclotrons

Nuclear Reactor

By End User

Hospitals

Diagnostic Imaging Centers

Ambulatory Surgical Centers

Cancer Research Institute

By Region:

North America

Latin America

Europe

Asia Pacific

Middle East, and Africa

Competitive Landscape:

The radiopharmaceuticals market is a moderately competitive presence of local as well as global companies. Some of the key players which are contributing to the growth of the market are

Siemens AG

Positron Corporation

Curium

GE Healthcare

Lantheus Holdings Inc.

Sotera Health LLC

Bayer AG

Eckert & Ziegler

Novartis AG, and BWX Technologies Inc.

The major players are adopting several growth strategies, such as product launches, acquisitions, and collaborations, which are contributing to the growth of the radiopharmaceutical market globally.

Siemens AG

Siemens is a technology company focused on industry, infrastructure, transport, and healthcare. From more resource-efficient factories, resilient supply chains, and smarter buildings and grids, to cleaner and more comfortable transportation as well as advanced healthcare, the company creates technology with purpose adding real value for customers. By combining the real and the digital worlds, Siemens empowers its customers to transform their industries and markets, helping them to transform the everyday for billions of people. Siemens also owns a majority stake in the publicly listed company Siemens Healthineers, a globally leading medical technology provider shaping the future of healthcare. In addition, Siemens holds a minority stake in Siemens Energy, a global leader in the transmission and generation of electrical power.

Recent Development

In 2021, NorthStar Medical Radioisotopes, LLC, a global radiopharmaceutical developer, and GE Healthcare confirmed an exclusive partnership to manufacture and distribute iodine-123 (I-123) capsules in the U.S. The product will assist GE Healthcare in enhancing its product portfolio and boosting its market position.

In 2021, Noria Therapeutics Inc. and PSMA Pharmaceuticals Inc. were acquired by Bayer AG Targeted both radiotherapy businesses are developing therapeutic and diagnostic radiopharmaceuticals. The acquisition is anticipated to add to Bayer's current nuclear medicine oncology portfolio.

Regional Analysis:

North America dominates the radiopharmaceuticals market because of the huge base of healthcare facilities and increasing overweight population base. Also, wide presence of a huge patient population suffering from chronic diseases such as coronary disorders, cancer, and strokes and rising number of research activities in this region are also boosting the market growth.

Asia-Pacific is expected to witness significant growth due to the growth in government initiatives to raise awareness and increasing research activities in the region. Also, growing availability of the well-established infrastructure, wide presence of major market players, growth in cases of cardiovascular diseases are boosting the growth rate of the market.

About DataM Intelligence:

DataM Intelligence 4Market Research is a market intelligence platform that gives access to syndicated, customized reports and consulting to its clients in one place. As a firm with rich experience in research and consulting across multiple domains, we are a one-stop solution that will cater to clients' needs in crucial business areas. DataM Intelligence has an online platform covering industries such as chemicals and materials, agriculture, health care services, animal feed, and food & beverages, among others. Our forum has Insights on markets that uncover the latest market research data distinct from the competition. With coverage across ten major industries in the marketplace research, DataM Intelligence benefits thousands of companies by helping them take their innovations early to the Market by providing a complete view of the Market with statistical forecasts. Our strategy-centric framework and value-added services will let individuals and corporates ease access and custom personalization to research and markets.

For more information: Sai Kiran

Sales Manager at DataM Intelligence

Email: [email protected]

Tel: +1 877 441 4866

Website: www.datamintelligence.com

#Radiopharmaceuticals Market #Radiopharmaceuticals

0 notes

billynor · 2 years

Text

0 notes

petnews2day · 2 years

Text

Use of Radiopharmaceuticals in Neurological Applications Presents Opportunities

New Post has been published on https://petn.ws/f6Rw

Use of Radiopharmaceuticals in Neurological Applications Presents Opportunities

Company Logo Dublin, Nov. 16, 2022 (GLOBE NEWSWIRE) — The “Nuclear Medicine Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2028” report has been added to ResearchAndMarkets.com’s offering. The report on the global nuclear medicine market provides qualitative and quantitative analysis for the period from 2020 to 2028. The report predicts the […]

See full article at https://petn.ws/f6Rw #PetFinancialNews

#Pet Financial News

0 notes

pujarathod · 2 years

Text

what is Nuclear Medicine or Radiopharmaceuticals Market?

Nuclear Medicine or Radiopharmaceuticals Market size is projected to reach USD 9.52 Billion by 2028 from an estimated USD 5.70 Billion in 2021, growing at a CAGR of 7.6% globally.

The "Global Nuclear Medicine or Radiopharmaceuticals Market by Type, Application and Region - Forecast to 2028" report has been added to Introspective Market Research offering. Growth in the nuclear medicine market can primarily be attributed to factors such as the increasing incidence and prevalence of cancer and cardiac ailments and initiatives to lessen the demand-supply gap of Mo-99. However, the short half-life of radiopharmaceuticals reduces their potential adoption, while hospital budget cuts and high equipment prices are expected to limit market growth to a certain extent.

In this report, the nuclear medicine market has been segmented based on type, application, procedure volume and region. Based on type, the nuclear medicine market is categorized into diagnostic and therapeutic nuclear medicine. The therapeutic nuclear medicine segment is further segmented into alpha emitters, beta emitters, and brachytherapy isotopes. The diagnostic nuclear medicine segment is segmented into SPECT and PET.

Key Prominent Players In The Nuclear Medicine or Radiopharmaceuticals Market:

· Actinium Pharmaceuticals Inc. (US)

· Alliance Medical (UK)

· Avid Bioservices Inc (US)

· Bayer HealthCare Pharmaceuticals (Germany)

· Bracco Diagnostics Inc. (Italy)

· Cardinal Health Inc. (US)

· GE Healthcare (US)

· Ion Beam Applications S.A (Belgium)

· Jubilant Pharma (India)

· Lantheus Medical Imaging Inc. (US)

· Medi-Radiopharma Ltd (Hungary)

· Nordion Inc. (Canada)

· Novartis/Advanced Accelerator Applications (France)

· Positron Corporation (US)

· Radiopharm Theranostics Ltd. (US)

Know More About The Global Trends Impacting The Future, Download A PDF Sample@:https://www.introspectivemarketresearch.com/request/15924

Market segmentation

The Nuclear Medicine or Radiopharmaceuticals market is segmented by type and application. Growth between segments over the period 2022-2028 provides accurate calculations and forecasts of revenue by type and application in terms of volume and value. This analysis can help you expand your business by targeting eligible niches.

Nuclear Medicine or Radiopharmaceuticals Market Segment by Types, Estimates, and Forecast by 2028

Diagnostic,Therapeutic,Research

Nuclear Medicine or Radiopharmaceuticals Market Segment by Applications, Estimates, and Forecast by 2028

Oncology,Thyroid,Cardiology,Neurology and Others

Regional Analysis for COVID-19 Outbreak-Global Nuclear Medicine or Radiopharmaceuticals Market:

APAC (Japan, China, South Korea, Australia, India, and Rest of APAC)

Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe)

North America (U.S., Canada, and Mexico)

South America (Brazil, Chile, Argentina, Rest of South America)

MEA (Saudi Arabia, UAE, South Africa)

We Offer Discount on The Nuclear Medicine or Radiopharmaceuticals Market Report @: https://www.introspectivemarketresearch.com/discount/15924

Industry experts have identified key factors influencing the pace of development of the Nuclear Medicine or Radiopharmaceuticals industry, including various opportunities and gaps. A thorough analysis of the Nuclear Medicine or Radiopharmaceuticals market for the growth trends of each category makes the overall study interesting. When studying the market, researchers also dig deep into their future prospects and their contribution to the industry. Additionally, the research report evaluated the market key players and features, such as capacity utilization rate comprised of revenue.

Nuclear Medicine or Radiopharmaceuticals Report provides insights into the following queries:

1.Market growth rate and growth momentum of Nuclear Medicine or Radiopharmaceuticals market for the period 2022-2028 2. The estimated size of the Nuclear Medicine or Radiopharmaceuticals market for the period 2022-2028 4. Sales (volume), revenue, and value analysis by regions of Nuclear Medicine or Radiopharmaceuticals market 5. The associated market risk, opportunity, and market overview of the Nuclear Medicine or Radiopharmaceuticals market 6. Major distributors, dealers, end-users, and traders of the Nuclear Medicine or Radiopharmaceuticals market?

Make An Inquiry For Report Customization (Must Use Business Contact Details For High Preference):https://www.introspectivemarketresearch.com/inquiry/15924

This study conducts a SWOT analysis to evaluate the strengths and weaknesses of key players in the Nuclear Medicine or Radiopharmaceuticals market. Additionally, the report performs a complex inspection of drivers and restraints operating in the market. The report also evaluates the observed trends in the parent market along with macroeconomic indicators, dominant factors and market attractiveness in relation to other segments. The report forecasts the impact of various industry aspects on the Nuclear Medicine or Radiopharmaceuticals market segments and regions.

Key Points Covered in Radiopharmaceuticals Market Study

· Market estimates and forecast 2022-2028

· Key drivers and restraints impacting market growth

· Segment-wise, Country-wise, and Region-wise Analysis

· Competition Mapping and Benchmarking

· Brand share and Market Share Analysis

· Key Radioisotope Innovations and Regulatory Climate

· COVID-19 Impact on Radiopharmaceuticals market and How to Navigate

· Recommendation on Key Winning Strategies

#Nuclear Medicine or Radiopharmaceuticals Market Nuclear Medicine or Radiopharmaceuticals Market Size Nuclear Medicine or Radiopharmaceutical

0 notes